Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2024

https://www.globenewswire.com/news-release/2024/06/03/2892256/0/en/Celularity-Presents-Data-of-The-Effect-of-Its-T-Cell-Platform-on-Multiple-Hematological-And-Solid-Tumors-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ:CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it presented in vivo data from its T-cell therapy platform at this year’s ASCO Annual Meeting in Chicago. These data show that PT-CD16VS, Celularity’s T-Cell preclinical asset, has potent in vitro and in vivo activity and has the potential to be combined with various monoclonal antibodies to target multiple cancers. Please find the link to the abstract here.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.